Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 by Richard Meehan as a drug-development entity focused on neurological disorders, notably migraine. The firm went public in 2017 and was largely acquired by Pfizer in October 2022 for $11.6B, retaining a holdco structure that now functions as a family office managing the remaining portfolio, royalties, and pipeline assets. Strategy centers on neurology and immunology drug development, with ongoing programs in CGRP receptor antagonists for migraine, glutamate modulators for depression, and TRPV4 antagonists for edema. The firm deploys capital through direct clinical-stage investments, licensing deals with partners like AbbVie, and royalty streams from approved drugs. Known co-investors include Royalty Pharma and Bain Capital during the Pfizer transaction. Geographic focus is primarily North America, with some European licensing partnerships. The team numbers around 80 employees, per public filings, spanning R&D, legal, and finance. Additional presence is minimal outside New Haven, though clinical operations extend to multiple US sites. Biohaven also maintains a charitable foundation, the Biohaven Foundation, funded by a portion of the Pfizer sale proceeds. In November 2024, the firm announced a licensing agreement with AbbVie for its glutamate modulator BHV-5000 for treatment-resistant depression (per Biohaven press release, November 2024). The structural differentiator is its hybrid identity: a publicly traded biotech company that acts as a family office, with the Meehan family and Dr. Coric controlling the board. This allows tax-advantaged capital deployment, access to public markets for future funding, and a transparent regulatory posture through SEC filings. Governance centers on the founder and CEO, with succession still tied to the original team.